Compositions containing nucleosides and manganese and their uses
This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
1. A method of protecting against a side effect of radiation exposure in a human subject comprising administration of a pharmaceutical composition comprising a protective amount of a protein-free D. radiodurans ultrafiltrate to the human subject, wherein the ultrafiltrate does not contain molecules having a molecular weight of greater than 3 kD.
2. The method of claim 1 , wherein the radiation exposure is selected from the group consisting of UV light, alpha radiation, beta radiation, gamma radiation, X-ray radiation, neutron radiation, and ionizing radiation.
3. The method of claim 1 , wherein the protein-free D. radiodurans ultrafiltrate contains one or more purine nucleosides selected from the group consisting of adenosine, uridine, β-pseudouridine, inosine, and mixtures thereof.
4. The method of claim 1 , wherein the protein-free D. radiodurans ultrafiltrate contains one or more antioxidants selected from the group consisting of manganese, MnCl 2 , and manganous phosphate.
5. The method of claim 1 , wherein the protein-free D. radiodurans ultrafiltrate further comprises an amino acid selected from the group consisting of alanine, valine and leucine.
6. The method of claim 1 , wherein the method prevents tissue damage due to radiation therapy.
7. The method of claim 3 , wherein the concentration of one or more purine nucleosides comprises about 1 to about 15 mM of adenosine and/or uridine.
8. The method of claim 4 , wherein concentration of the one or more antioxidants comprises about 1 to 12.5 mM of manganese.
9. A method of treating a side effect of radiation therapy in a human subject in need thereof comprising administration of a pharmaceutical composition comprising a protective amount of a protein-free D. radiodurans ultrafiltrate to the human subject, wherein the ultrafiltrate does not contain molecules having a molecular weight of greater than 3 kD.
10. The method of claim 9 , wherein the radiation is selected from the group consisting of UV light, alpha radiation, beta radiation, gamma radiation, X-ray radiation, neutron radiation, and ionizing radiation.
11. The method of claim 9 , wherein the protein-free D. radiodurans ultrafiltrate contains one or more purine nucleosides selected from the group consisting of adenosine, uridine, β-pseudouridine, inosine, and mixtures thereof.
12. The method of claim 9 , wherein the protein-free D. radiodurans ultrafiltrate contains one or more antioxidants selected from the group consisting of manganese, MnCl 2 and manganous phosphate.
13. The method of claim 9 , wherein the D. radiodurans ultrafiltrate further comprises an amino acid selected from the group consisting of alanine, valine, and leucine.
14. The method of claim 9 , wherein the method prevents tissue damage due to radiotherapy.
15. The method of claim 11 , wherein the concentration of one or more purine nucleosides comprises about 1 to about 15 mM of adenosine and/or uridine.
16. The method of claim 12 , wherein concentration of the one or more antioxidants comprises about 1 to about 12.5 mM of manganese.
17. The method of claim 9 , wherein the D. radiodurans ultrafiltrate extract is produced by a method comprising the steps of:
harvesting a D. radiodurans culture by centrifugation;
lysing the D. radiodurans culture to create a D. radiodurans lysate;
washing the D. radiodurans lysate;
centrifuging the D. radiodurans lysate for a time and under conditions sufficient to create a supernatant;
passing the supernatant through a less than 3 kiloDalton filter; and
boiling the supernatant for about 15 to about 45 minutes,
wherein the extract is soluble in butanol, resistant to boiling, and cell-free.
18. The method of claim 1 , wherein the pharmaceutical composition is administered topically to the human subject.
19. The method of claim 9 , wherein the pharmaceutical composition is administered topically to the human subject.